This page shows the latest Nasal polyps news and features for those working in and with pharma, biotech and healthcare.
The drug was first launched for atopic dermatitis in 2016, and has since scored label extensions including adolescent AD patients, asthma and chronic rhinosinusitis with nasal polyps.
First launched for atopic dermatitis in 2016, label extensions to include adolescent AD patients as well as asthma and chronic rhinosinusitis with nasal polyps helped sales of Regeneron-partnered Dupixent (dupilumab)
This included a 57% and 51% improvement in nasal congestion/obstruction severity, compared to 19% and 15% in the placebo groups in SINUS-24 and SINUS-52. ... It also demonstrated a 33% and 27% reduction in participant’s nasal polyps score compared to a
Nasal polyps can lead to loss of smell and often patients require surgery to remove the polyps,” said the agency’s head of pulmonary, allergy and rheumatology products Sally Seymour. ... Trials of the drug in nasal polyps have showed that it could
The companies have big plans for the drug, researching its clinical benefit in other diseases driven by allergic and other type 2 inflammation, including chronic rhinosinusitis with nasal polyps. ... A phase 3 showed that Dupixent significantly improved
Meanwhile, Sanofi and development partner Regeneron have also just reported new data in patients with rhinosinusitis and nasal polyps which could expand its use further.
More from news
Approximately 1 fully matching, plus 9 partially matching documents found.
Having too many eosinophils in certain tissues is an important contributor to a range of conditions including severe eosinophilic asthma (SEA), nasal polyps, eosinophilic oesophagitis and rarer, systemic diseases such as ... surgery but whose nasal
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...